Protocols and risks: when less is more

Jaspreet Pannu¹, Jonas B Sandbrink², Matthew Watson³, Megan J Palmer^{4

5}, David A Relman^{6

7

8

9}

Affiliations

¹ Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. pannu@stanford.edu.
² Medical Sciences Division, University of Oxford, Oxford, UK.
³ Center for Health Security, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁴ Department of Bioengineering, Stanford University, Stanford, CA, USA.
⁵ Center for International Security and Cooperation, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CA, USA.
⁶ Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. relman@stanford.edu.
⁷ Center for International Security and Cooperation, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CA, USA. relman@stanford.edu.
⁸ Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA. relman@stanford.edu.
⁹ Infectious Diseases Section, Veterans Affairs Health Care System, Palo Alto, CA, USA. relman@stanford.edu.

Comment

Jaspreet Pannu et al. Nat Protoc. 2022 Jan.

. 2022 Jan;17(1):1-2.

doi: 10.1038/s41596-021-00655-6. Epub 2021 Dec 6.

Jaspreet Pannu¹, Jonas B Sandbrink², Matthew Watson³, Megan J Palmer^{4

5}, David A Relman^{6

7

8

9}

¹ Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. pannu@stanford.edu.
² Medical Sciences Division, University of Oxford, Oxford, UK.
³ Center for Health Security, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁴ Department of Bioengineering, Stanford University, Stanford, CA, USA.
⁵ Center for International Security and Cooperation, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CA, USA.
⁶ Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. relman@stanford.edu.
⁷ Center for International Security and Cooperation, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CA, USA. relman@stanford.edu.
⁸ Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA. relman@stanford.edu.
⁹ Infectious Diseases Section, Veterans Affairs Health Care System, Palo Alto, CA, USA. relman@stanford.edu.

No abstract available

Comment on

Engineering SARS-CoV-2 using a reverse genetic system.
Xie X, Lokugamage KG, Zhang X, Vu MN, Muruato AE, Menachery VD, Shi PY. Xie X, et al. Nat Protoc. 2021 Mar;16(3):1761-1784. doi: 10.1038/s41596-021-00491-8. Epub 2021 Jan 29. Nat Protoc. 2021. PMID: 33514944 Free PMC article. Review.

1. Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. Nat. Protoc. 16, 1761–1784 (2021). - DOI
1. Perrow, C. Normal Accidents: Living with High Risk Technologies updated edn (Princeton University Press, 2011).
1. Petersen, E. et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. Dis. 20, e238–e244 (2020). - DOI
1. Amarilla, A. A. et al. A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses. Nat. Commun. 12, 3431 (2021). - DOI
1. US Department of Health and Human Services. Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens. https://www.phe.gov/s3/dualuse/documents/p3co.pdf (2017).